Invention Grant
US09580456B2 Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
有权
半乳凝素-3半乳糖苷抑制剂及其用于治疗肺纤维化的用途
- Patent Title: Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
- Patent Title (中): 半乳凝素-3半乳糖苷抑制剂及其用于治疗肺纤维化的用途
-
Application No.: US14438977Application Date: 2013-10-30
-
Publication No.: US09580456B2Publication Date: 2017-02-28
- Inventor: Ulf Nilsson , Hakon Leffler , Neil Henderson , Tariq Sethi , Alison MacKinnon
- Applicant: GALECTO BIOTECH AB , UNIVERSITY OF EDINBURGH
- Applicant Address: DK Copenhagen
- Assignee: Galecto Biotech AB
- Current Assignee: Galecto Biotech AB
- Current Assignee Address: DK Copenhagen
- Agency: Agris & von Natzmer, LLP
- Agent Cheryl H. Agris
- Priority: CA2794066 20121031; CA2795793 20121115
- International Application: PCT/EP2013/072691 WO 20131030
- International Announcement: WO2014/067986 WO 20140508
- Main IPC: A61K31/7016
- IPC: A61K31/7016 ; A61K31/7056 ; A61M15/00 ; C07H19/056 ; C07H3/04 ; G01N33/68 ; A61K9/00 ; A61K31/7008 ; C07H5/10
Abstract:
The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.
Public/Granted literature
- US20150274764A1 Galactoside Inhibitor of Galectin-3 and its use for Treating Pulmonary Fibrosis Public/Granted day:2015-10-01
Information query
